HER-2 and topoisomerase IIa gene alterations in male breast cancer.

AbstractTreatment principles of breast cancer in males are derived from studies performed among females, while the low incidence in males has so far precluded such studies. The therapy recommendations for males therefore lack the solid evidence, frequently present for females with breast cancer. The primary breast cancer diagnosis in males is not infrequently in stage III/IV and at higher age, thereby requiring multiprofessional and multimodal management including preoperative therapy and adjuvant therapies based on the tumour’s biological characteristics and the clinical circumstances. The majority of male breast cancer tumours are oestrogen-receptor positive and adjuvant/neoadjuvant tamoxifen is therefore recommended, surgery is frequently radical mastectomy and adjuvant radiotherapy should likely be used on wider indications. Chemotherapy should be considered both in the adjuvant and metastatic setting for receptor-negative cancers and for patients with biologically aggressive disease. Trastuzumab should be offered to patients with Her-2/neu-positive disease, while the use of aromatase inhibitors is more uncertain due to differences in the hormonal environment in males.

Download Full-text

Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer

Scientific Reports ◽

10.1038/s41598-021-04342-0 ◽

2022 ◽

Vol 12 (1) ◽

Author(s):

Nan Yao ◽

Wenzai Shi ◽

Tong Liu ◽

Sarah Tan Siyin ◽

Weiqi Wang ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Competing Risks ◽

Male Breast Cancer ◽

Cox Regression ◽

Female Breast Cancer ◽

Male Breast ◽

Limited Information ◽

Female Breast ◽

Her 2

AbstractMale breast cancer (MBC) is rare. Due to limited information, MBC has always been understudied. We conducted a retrospective population-based cohort study using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. The clinical and biological features of female breast cancer (FBC) patients were compared with MBC patients. Cox regression models and competing risks analyses were used to identify risk factors associated with cancer-related survival in MBC and FBC groups. Results showed that MBC patients suffered from higher TNM stages, tumor grades, and a higher percentage of hormone receptor-positive tumors, compared with FBC patients (all p < 0.05). In addition, the breast tumor locations varied a lot between males and females (p < 0.05). FBC patients were associated with superior overall survival than MBC patients. Results from multivariate cox regression and competing risks analyses showed age, race, T, N, M-stages, tumor grades, estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) overexpression were independent prognosis factors in FBC patients (all p < 0.05). MBC patients had similar risk factors to FBC patients, but PR and HER-2 status did not independently influence survival (all p > 0.05). Tumor location was an independent prognostic factor for both gender groups.

Download Full-text

Male breast cancer: a 5-year experience from a State Cancer Institute

International Surgery Journal ◽

10.18203/2349-2902.isj20213209 ◽

2021 ◽

Author(s):

Shashi Singh Pawar ◽

Manish Kumar ◽

Kunal Kishor ◽

Nadeem Ahmad ◽

Sanjeet Kumar Singh ◽

...

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Ductal Carcinoma ◽

Radical Mastectomy ◽

Female Breast Cancer ◽

Male Breast ◽

Biological Behavior ◽

Clinicopathological Profile ◽

Her 2 ◽

Male Patients

Background: Male breast cancer (MBC) is an uncommon malignancy accounting for <1% of all cancers in men and <1 % of overall breast cancer cases. Although there are many similarities between MBC and female breast cancer (FBC), they are not identical in clinical behaviour. There is need to understand the exact biological behavior of MBC.Methods: A retrospective observational study was done at State Cancer Institute, IGIMS, Patna which included all MBC patients registered during a 5-year study period (January 2016 to April 2021). 16 consecutive cases of MBC were identified and their detailed clinicopathological profile was analyzed.Results: MBC accounted for 1.10% of the total breast cancer cases. The median age of presentation was 58 years. Most common presentation was lump. Invasive ductal carcinoma (IDC) was most common histology. Majority of the patient presented to us in advanced stage. Estrogen receptor (ER)/progesterone receptor (PR) status was found to be positive in 12 patients. HER-2/neu receptor was positive in 4 patients. 2 patients had triple negative disease (TNBC) status. Surgery in the form of modified radical mastectomy (MRM) was done in 10 patients. All patients received adjuvant therapy as per NCCN guidelines.Conclusions: MBC is rare disease presenting at a relatively early age in Indian male patients. Most of them have positive ER/PR status. As outcomes have not improved comparatively, there is a need to evolve separate guidelines for MBC.

Download Full-text